These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28787714)

  • 1. Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target.
    Wang Y; Yan T; Lu H; Yin W; Lin B; Fan W; Zhang X; Fernandez-Funez P
    Neurodegener Dis; 2017; 17(6):242-250. PubMed ID: 28787714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-beta immunotherapy: the hope for Alzheimer disease?
    Barrera-Ocampo A; Lopera F
    Colomb Med (Cali); 2016 Dec; 47(4):203-212. PubMed ID: 28293044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Alzheimer disease: the challenge of adverse effects.
    Liu YH; Giunta B; Zhou HD; Tan J; Wang YJ
    Nat Rev Neurol; 2012 Aug; 8(8):465-9. PubMed ID: 22751529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.
    Panza F; Solfrizzi V; Imbimbo BP; Tortelli R; Santamato A; Logroscino G
    Expert Rev Clin Immunol; 2014 Mar; 10(3):405-19. PubMed ID: 24490853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.
    Nitsch RM; Hock C
    Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
    Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
    Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.
    van Dyck CH
    Biol Psychiatry; 2018 Feb; 83(4):311-319. PubMed ID: 28967385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.
    Murakami K
    Biosci Biotechnol Biochem; 2014; 78(8):1293-305. PubMed ID: 25130729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
    Cehlar O; Skrabana R; Revajova V; Novak M
    Bratisl Lek Listy; 2018; 119(4):201-204. PubMed ID: 29663816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
    Rygiel K
    Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients.
    Lambracht-Washington D; Rosenberg RN
    Neurobiol Aging; 2015 Mar; 36(3):1274-81. PubMed ID: 25725942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?
    Lemere CA; Masliah E
    Nat Rev Neurol; 2010 Feb; 6(2):108-19. PubMed ID: 20140000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Aβ immunotherapy for Alzheimer's disease].
    Sakai K; Yamada M
    Brain Nerve; 2013 Apr; 65(4):461-8. PubMed ID: 23568994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?
    Tayeb HO; Murray ED; Price BH; Tarazi FI
    Expert Opin Biol Ther; 2013 Jul; 13(7):1075-84. PubMed ID: 23574434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.
    Panza F; Frisardi V; Imbimbo BP; Seripa D; Solfrizzi V; Pilotto A
    Expert Opin Biol Ther; 2011 Jun; 11(6):679-86. PubMed ID: 21501112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.